Tag: papillary renal cell carcinoma (PRCC)

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

byConstance Wu

March 11, 2021

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

byNeel Mistryand1 others

June 25, 2021

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result